Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Companyâ€™s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Closed - Nasdaq 04:00:00 18/05/2024 HKT			5-day change	1st Jan Change
15.13 ^USD	-0.13%		-.--%	-

21/05/24	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P Global BMI Index	CI
21/05/24	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P TMI Index	CI

Market Cap	224M 194M 183M 166M 311M 21.45B 314M 2.19B 842M 10.88B 840M 822M 34.59B	P/E 2022	-100x	P/E 2023	-162x
Enterprise Value	205M 178M 168M 152M 285M 19.64B 287M 2B 771M 9.96B 769M 753M 31.67B	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	98.81%	Yield 2022 *	-	Yield 2023	-

21/05/24	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P Global BMI Index	CI
21/05/24	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P TMI Index	CI
17/05/24	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from NASDAQ Composite Index	CI
16/05/24	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
09/05/24	Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024	CI
28/03/24	Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	MT
08/03/24	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
14/02/24	Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	MT
14/02/24	Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	DJ
17/11/23	Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing	MT
03/11/23	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
18/09/23	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index	CI
10/08/23	Insider Buy: Merrimack Pharmaceuticals	MT

13/05/24	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution and Cash Liquidating Dividend Amount of $15.10 per Share of Common Stock	AQ
11/05/24	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock	BU
09/05/24	Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution	BU
01/05/24	Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution	BU
28/03/24	Merrimack Receives $225 Million Milestone Payment from Ipsen	BU

Merrimack Pharmaceuticals Stock

Stocks

MACK

US5903282094

Biotechnology & Medical Research

Valuation: Merrimack Pharmaceuticals

Latest news: Merrimack Pharmaceuticals

Press Releases: Merrimack Pharmaceuticals

News in other languages: Merrimack Pharmaceuticals

Quotes and Performance

Price Extremes

Managers and Directors: Merrimack Pharmaceuticals

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
Gary Crocker CEO	Chief Executive Officer	74	28/06/2019
Timothy Surgenor IRC	Investor Relations Contact	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
26/12/23	Western Standard LLC	Buy	Company	49,550	0.3460%
7/12/23	Western Standard LLC	Buy	Company	101,050	0.7056%
17/11/23	Western Standard LLC	Buy	Company	300	0.0021%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MERRIMACK PHARMACEUTICALS	-0.13%	-.--%	-.--%	+21.92%	224M
LONZA GROUP AG	+0.56%	-4.71%	-2.45%	+9.18%	45.48B
REVOLUTION MEDICINES, INC.	+0.66%	-2.34%	+340.62%	+530.14%	43.68B
IQVIA HOLDINGS INC.	+1.49%	-0.78%	+41.90%	+24.75%	43.09B
BEONE MEDICINES AG	+2.11%	-1.24%	+9.09%	+78.25%	39.4B
CELLTRION, INC.	+0.34%	-4.03%	+9.34%	+38.90%	31.91B
ASCENDIS PHARMA A/S	+0.53%	-2.08%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+1.34%	+0.70%	+21.35%	+112.62%	16.4B
EUROFINS SCIENTIFIC SE	+2.07%	+0.78%	+13.07%	+30.91%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.85%	-5.33%	+78.63%	+31.45%	13.28B
Average	+0.71%	-2.17%	+56.84%	+97.57%	26.5B
Weighted average by Cap.	+0.94%	-2.82%	+75.93%	+127.87%

	2022	2023
Net sales	-	-
Net income	-1.54M -1.34M -1.26M -1.15M -2.15M -148M -2.16M -15.08M -5.81M -75.07M -5.8M -5.67M -239M	-1.18M -1.02M -966K -876K -1.64M -113M -1.66M -11.53M -4.44M -57.42M -4.44M -4.34M -183M
Net Debt	-19.44M -16.84M -15.9M -14.42M -27.05M -1.86B -27.25M -190M -73.15M -945M -73.01M -71.4M -3B	-18.88M -16.36M -15.43M -14M -26.27M -1.81B -26.46M -184M -71.03M -918M -70.89M -69.33M -2.92B

3 years	12	15.89
5 years	3	15.89
10 years	1.49	67.9